Gentian Diagnostics Q3 Sales Rise 22% to NOK 51.1 Million

PUBT · 2d ago
Gentian Diagnostics Q3 Sales Rise 22% to NOK 51.1 Million
  • Gentian Diagnostics’ third-quarter 2026 sales rose 22% to NOK 51.1 million.
  • EBITDA increased to NOK 13.6 million from NOK 8.4 million a year earlier.
  • The EBITDA margin reached 27%; gross margin improved to 61%.
  • Year-to-date net loss totaled NOK 8.5 million, reflecting a NOK 30.2 million impairment tied to the discontinued NT-proBNP project.
  • Operating cash flow for the nine months fell to NOK -0.9 million from NOK 16.5 million a year earlier.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gentian Diagnostics ASA published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202610200200OSLOBORSNEWS__EN_C617793521E1352E1DB7F3DC6359F25), on October 20, 2026, and is solely responsible for the information contained therein.